^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QLS31905

    i
    Associations
    News

    Trials

    Company:
    Qilu Pharma
    Drug class:
    CD3 agonist, CLDN18.2 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors (NCT06041035)
    Phase 1/2
    Qilu Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    09/18/2023
    Initiation :
    10/01/2023
    Primary completion :
    10/01/2024
    Completion :
    10/01/2025
    CLDN18
    |
    cisplatin • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • QLS31905